https://english.news.cn/20240207/0b3c68bf37fc4d8cb0726f14583ed7f3/c.html
The center, managed by Peking University, is located in Huairou Science City in the northeastern suburbs of Beijing.
With a planned construction area of 29,000 square meters and a total investment of approximately 630 million yuan (about 88.67 million U.S. dollars), the center is a key part of the multi-modal and multi-scale biomedical imaging project, one of the major national scientific and technological infrastructure, It is scheduled to be put into operation in June 2026.
Molecular imaging technology can decode the occurrence and development mechanism of diseases in real-time and in vivo from different scales of molecules, cells and tissue, and realize the visual diagnosis and treatment of diseases. It has shown great clinical significance in the diagnosis and treatment of diseases such as prostate cancer and neuroendocrine tumors. Core technology is the use of molecular tracers with specific biological targeting properties.
The platform comprises four experimental sub-platforms, namely, in vivo chemistry and probe technology, biological imaging probes, multi-modal imaging probes, and medical diagnostic probes, alongside a public lab sub-platform.